Efficacy of synthetic surfactant (CHF5633) bolus and/or lavage in meconium-induced lung injury in ventilated newborn rabbits
- PMID: 35701606
- DOI: 10.1038/s41390-022-02152-2
Efficacy of synthetic surfactant (CHF5633) bolus and/or lavage in meconium-induced lung injury in ventilated newborn rabbits
Abstract
Background: The pathogenesis of neonatal meconium aspiration syndrome (MAS) involves meconium-induced lung inflammation and surfactant inactivation. Bronchoalveolar lavage (BAL) with diluted surfactant facilitates the removal of meconium. CHF5633, one of the most promising synthetic surfactants, is effective in neonatal respiratory distress syndrome. Here we investigated its efficacy via BAL in an experimental MAS model.
Methods: Experimental MAS was induced at birth in near-term newborn rabbits by intratracheal instillation of reconstituted human meconium. First, undiluted CHF5633 was compared with a porcine-derived surfactant (Poractant alfa) via intratracheal bolus (200 mg/kg). Second, the efficacy of BAL with diluted CHF5633 (5 mg/mL, 20 ml/kg) alone, or followed by undiluted boluses (100 or 300 mg/kg), was investigated.
Results: Meconium instillation caused severe lung injury, reduced endogenous surfactant pool, and poor survival. CHF5633 had similar benefits in improving survival and alleviating lung injury as Poractant alfa. CHF5633 BAL plus higher boluses exerted better effects than BAL or bolus alone in lung injury alleviation by reversing phospholipid pools and mitigating proinflammatory cytokine mRNA expression, without fluid retention and function deterioration.
Conclusions: CHF5633 improved survival and alleviated meconium-induced lung injury, the same as Poractant alfa. CHF5633 BAL plus boluses was the optimal modality, which warrants further clinical investigation.
Impact: To explore the efficacy of a synthetic surfactant, CHF5633, in neonatal lung protection comparing with Poractant alfa in a near-term newborn rabbit model with meconium-induced lung injury. Similar effects on improving survival and alleviating lung injury were found between CHF5633 and Poractant alfa. Optimal therapeutic effects were identified from the diluted CHF5633 bronchoalveolar lavage followed by its undiluted bolus instillation compared to the lavage or bolus alone regimens. Animals with CHF5633 lavage plus bolus regimen exerted neither substantial lung fluid retention nor lung mechanics deterioration but a trend of higher pulmonary surfactant-associated phospholipid pools.
© 2022. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.
Similar articles
-
Effects of Natural versus Synthetic Surfactant with SP-B and SP-C Analogs in a Porcine Model of Meconium Aspiration Syndrome.Neonatology. 2014;105(2):128-35. doi: 10.1159/000356065. Epub 2013 Dec 14. Neonatology. 2014. PMID: 24356240
-
In vitro and in vivo comparison between poractant alfa and the new generation synthetic surfactant CHF5633.Pediatr Res. 2017 Feb;81(2):369-375. doi: 10.1038/pr.2016.231. Epub 2016 Nov 3. Pediatr Res. 2017. PMID: 27973472
-
Impact of synthetic surfactant CHF5633 with SP-B and SP-C analogues on lung function and inflammation in rabbit model of acute respiratory distress syndrome.Physiol Rep. 2021 Jan;9(1):e14700. doi: 10.14814/phy2.14700. Physiol Rep. 2021. PMID: 33403805 Free PMC article.
-
Surfactant therapy for meconium aspiration syndrome: current status.Drugs. 2005;65(18):2569-91. doi: 10.2165/00003495-200565180-00003. Drugs. 2005. PMID: 16392874 Review.
-
Neonatal surfactant therapy beyond respiratory distress syndrome.Semin Fetal Neonatal Med. 2023 Dec;28(6):101501. doi: 10.1016/j.siny.2023.101501. Epub 2023 Nov 23. Semin Fetal Neonatal Med. 2023. PMID: 38040584 Review.
Cited by
-
The Synthetic Surfactant CHF5633 Restores Lung Function and Lung Architecture in Severe Acute Respiratory Distress Syndrome in Adult Rabbits.Lung. 2024 Jun;202(3):299-315. doi: 10.1007/s00408-024-00689-z. Epub 2024 Apr 29. Lung. 2024. PMID: 38684519 Free PMC article.
-
What is new in synthetic lung surfactant protein technology?Expert Rev Respir Med. 2024 Dec;18(12):913-917. doi: 10.1080/17476348.2024.2429669. Epub 2024 Nov 17. Expert Rev Respir Med. 2024. PMID: 39534910 No abstract available.
References
-
- Lindenskov, P. H., Castellheim, A., Saugstad, O. D. & Mollnes, T. E. Meconium aspiration syndrome: possible pathophysiological mechanisms and future potential therapies. Neonatology 107, 225–230 (2015). - DOI
-
- Sun, B., Shao, X., Cao, Y., Xia, S. & Yue, H. Neonatal-perinatal medicine in a transitional period of China. Arch. Dis. Child. Fetal Neonatal Ed. 98, 440–444 (2013). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical